Hotpot AI graphics Boehringer/Eli Lilly launches sixth heart failure study of SGLT2 inhibitor Jardiance CStone Pharmaceuticals Completes Dosing of Fi ...

Stocks rally after inflation data but close lower for the week December 21, 2024 The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for ...

Zepbound, as expected, was more effective in promoting weight loss. Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...